# HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

> **NCT05409378** · NA · WITHDRAWN · sponsor: **HLT Inc.**

## Conditions studied

- Aortic Regurgitation

## Interventions

- **DEVICE:** The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)

## Key facts

- **NCT ID:** NCT05409378
- **Lead sponsor:** HLT Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-08
- **Primary completion:** 2023-01-20
- **Final completion:** 2023-01-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** HLT Business Decision
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05409378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05409378, "HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05409378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*